Cost-effectiveness analysis of screening adolescent males for Chlamydia on admission to detention.
BACKGROUND
Chlamydia trachomatis infections can lead to serious and costly sequelae. Because chlamydia is most often asymptomatic, many infected youth do not seek testing. Entry to a detention system provides an opportunity to screen and treat many at-risk youth. GOAL The goal of this study was to determine the cost-effectiveness of screening male youth for chlamydia on entry to detention.


METHODS
Incremental cost-effectiveness of 3 chlamydia screening strategies was compared for a hypothetical cohort of 4000 male youth per year: 1) universal chlamydia screening using a urine-based nucleic acid amplification test (NAAT), 2) selective NAAT screening of urine leukocyte esterase (LE)-positive urines, and 3) no screening. The model incorporated programmatic costs of screening and treatment and medical cost savings from sequelae prevented in infected males and female partners. The analysis was conducted from the healthcare system perspective.


RESULTS
Chlamydia prevalence in the sampled population of 594 was 4.8%, and the average number of female sexual partners/infected male was 1.6. Universal NAAT screening was the most cost-effective strategy, preventing 37 more cases of pelvic inflammatory disease (PID) and 3 more cases of epididymitis than selective screening and saving an additional 24,000 dollars. The analysis was sensitive to NAAT cost, LE sensitivity, rate of PID development, PID sequelae cost, and number of female partners. Universal screening remained the most cost saving for prevalence as low as 2.8% or higher.


CONCLUSIONS
Universal chlamydia screening of adolescent males on entry to detention was the most cost-effective strategy. Savings are primarily the result of the prevention of PID in recent and future partners of index males. Screening detained male youth using a urine-based NAAT provides a public health opportunity to significantly reduce chlamydia infections in youth at risk for sexually transmitted diseases.
Blake
Diane R
DR
Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA. Diane.Blake@umassmed.edu
Gaydos
Charlotte A
CA
Quinn
Thomas C
TC
D000293:Adolescent; D000294:Adolescent Behavior; D016497:Adolescent Health Services / Q000191:economics*; D002690:Chlamydia Infections / Q000453:epidemiology / Q000517:prevention & control* / Q000652:urine; D002692:Chlamydia trachomatis / Q000302:isolation & purification; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D003663:Decision Trees; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics* / Q000379:methods; D008404:Massachusetts / Q000453:epidemiology; D015995:Prevalence; D011329:Prisoners; D016482:Urinalysis / Q000191:economics / Q000706:statistics & numerical data